Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.53 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125612 | 0.83 | CHEK1 (0.47) | PGRCHEK1ALOX5APFEN1RARB | |
| SCHEMBL5125606 | 0.83 | CHEK1 (0.47) | PGRCHEK1ALOX5APFEN1RARB | |
| SCHEMBL4426122 | 0.81 | PGR (0.62) | PGRRARBRARGRXRATDP2 | |
| SCHEMBL4420953 | 0.81 | PGR (0.77) | PGRRARBRARGRXRATDP2 | |
| SCHEMBL4416529 | 0.80 | PGR (0.69) | PGRALOX5APFEN1RARBRARG | |
| SCHEMBL4426130 | 0.80 | PGR (0.67) | PGRCHEK1RARBRARGTDP2 | |
| SCHEMBL4426615 | 0.77 | PGR (0.64) | PGRALOX5APFEN1HSD17B3 | |
| SCHEMBL4429209 | 0.75 | PGR (0.67) | PGRTDP2PDK2 | |
| SCHEMBL4417754 | 0.74 | PGR (0.77) | PGRRARBRARGRXRATDP2 | |
| SCHEMBL4426105 | 0.73 | PGR (0.78) | PGRKDRFLT3GSK3BTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325916-A1 | 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-20080119537-A1 | 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-7319152-B2 | Contraception, hormone replacement therapy, cycle-related symptoms, or benign or malignant neoplastic disease; -methyl-5-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrrole-2-carbonitrile | WYETH (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | PGR, CYP19A1, GNRHR | PGR 1/4885CHEK1 2588/4885ALOX5AP 2089/4885 |
| US-20090325916-A1 | 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS | CYP19A1, PGR, NR5A1 | PGR 2/4885CHEK1 3351/4885ALOX5AP 973/4885 |
| US-20080119537-A1 | 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators | CYP19A1, PGR, NR5A1 | PGR 2/4885CHEK1 3517/4885ALOX5AP 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.